曲妥珠单抗联合ECT化疗方案对晚期乳腺癌患者疗效、血清CA153、CEA及造血功能影响

Effect of trastuzumab combined with ECT chemotherapy regimen on efficacy,serum CA153,CEA and hematopoietic function in patients with advanced breast cancer

目的 探讨曲妥珠单抗联合表柔比星(E)+环磷酰胺(C)+紫杉醇(T)化疗方案对晚期乳腺癌患者疗效、血清癌抗原153(CA153)、癌胚抗原(CEA)及造血功能的影响。方法 选择安徽阜南县人民医院2019年10月至2022年10月收治的60例晚期乳腺癌患者,按照随机数表法分为ECT组30例(接受表柔比星+环磷酰胺、多西他赛治疗)和联合组30例(ECT组基础上使用曲妥珠单抗),比较两组临床疗效、血清CA153、CEA、造血功能、不良反应。结果 联合组有效率高于ECT组(96.67%vs. 80.00%),差异有统计学意义(χ^(2)=4.043,P<0.05)。两组血清CA153、CEA均较治疗前降低,疗程结束时,联合组上述水平低于ECT组,差异有统计学意义(t=14.795、17.472,P<0.05)。两组血小板计数(PLT)、血红蛋白(Hb)、白细胞计数(WBC)均较治疗前降低,疗程结束时,两组上述指标及不良反应比较差异无统计学意义(t=1.052、1.751、1.676,P>0.05)。结论 相较于单一使用ECT化疗方案,ECT化疗方案联合曲妥珠单抗可以提高晚期乳腺癌患者临床疗效,降低血清CA153、CEA水平,且不会对患者造血功能造成影响。

Objective To investigate the impact of trastuzumab combined with epirubicin(E),cyclophosphamide(C)and taxol(T)chemotherapy on therapeutic effects,serum carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA)and hematopoietic function in patients with advanced breast can-cer.Methods A total of 60 patients with advanced breast cancer who were admitted to Funan County People's Hospital in Anhui Province from October 2019 to October 2022 were selected.They were divided into two groups:the ECT group(30 patients receiving ECT chemotherapy)and the combination group(30 patients treated with trastuzumab in addition to ECT chemotherapy),based on a random number table.Clinical effica-cy,serum levels of CA153 and CEA,hematopoietic function,and adverse reactions were compared between the two groups.Results The effective rate in the combination group was higher than that in the ECT group(96.67%vs.80.00%),with a statistically significant difference(χ^(2)=4.043,P<0.05).After treatment,serum CA153 and CEA levels in both groups decreased.By the end of the treatment course,serum CA153 and CEA levels in the combination group were lower than those in the ECT group,with statistically significant differenc-es(t=14.795,17.472,P<0.05).Platelet count(PLT),hemoglobin(Hb),and white blood cell count(WBC)decreased in both groups after treatment.At the end of the treatment course,there were no statistically significant differences in the above indicators or the incidence of adverse reactions between the two groups(t=1.052,1.751,1.676,P>0.05).Conclusion Compared to using ECT chemotherapy alone,combining ECT chemotherapy with trastuzumab can enhance the clinical outcomes for patients with advanced breast cancer.This combination treatment also lowers serum CA153 and CEA levels without impacting hematopoietic and im-mune functions.